Chicago, Illinois 60612


Purpose:

The purpose of this pilot study is to test the safety of oral ketamine to treat acute pain after amputation surgery. The objective of the proposed research is to conclusively determine if oral ketamine is a safe alternative analgesic to opioid for acute pain in subjects undergoing elective amputation of the lower extremity. All participants will receive oral ketamine.


Study summary:

A prospective open-label clinical trial to decrease the incidence of expected side effects of oral ketamine dose administered presurgery and postsurgery, in 10 subjects undergoing elective amputation of the lower extremity. The primary outcome measure is the incidence of adverse events. Secondary outcome measures are decreased acute pain levels and decreased incidence of stump and phantom limb pain at 6 months. Enrollment of participants will occur at Rush University Medical Center (Rush), Chicago, IL. Consented participants will be included in the study undergoing elective amputation of the lower extremity from all causes. Rationale for using oral ketamine for acute pain after amputation surgery: The common analgesic, morphine, has a narrow therapeutic window and numerous side effects.1 Ketamine, is a chemically stable compound, non-opioid with analgesic properties at low doses. In addition, ketamine stimulates the cardio-respiratory system which is of great benefit in injured patients.2-4 Ketamine is generally administered by the intravenous (IV) route and provides analgesia via antagonism of the N-Methyl-D-Asparate (NMDA) receptor. Ketamine has the added benefit of a wide therapeutic safety index. IV ketamine has been shown to provide postoperative analgesia in many clinical trials; in particular to reduce opioid consumption.5 Severe acute pain has been shown to progress to chronic pain due to central sensitization.6 Perioperative IV ketamine has been shown in limited studies to decrease the incidence of chronic pain after surgery. However, the IV route of administration of ketamine has limitations due to difficulties with IV placement in certain tactical situations. Therefore, the use of oral ketamine (non-opioid) for the purpose of acute pain management after trauma or surgery is highly desirable. Pharmacokinetic studies: Oral ketamine may seem disadvantageous because of 17% bioavailability, mainly due to first-pass drug metabolism in the liver. However, there is not a wide variability in bioavailability from patient-to-patient (mean 16.6%, SE = 2.8%) and hence a predictable oral dosing can be achieved. Although investigators have tested formulations with sublingual or buccal transmucosal administration of ketamine, in practice they fail to increase the ketamine bioavailability versus oral ketamine. Ketamine as nasal spray is problematic for acute use, since the amount of drug is difficult to control using an atomizer. Day 1 (day of surgery) Before Surgery: An analgesic dose of the oral ketamine (1.0 mg/kg) will be administered one hour before surgery in the preoperative holding area. If the subject is experiencing any adverse events (e.g. hallucinations) from the 1.0 mg/kg pre-surgery dose of ketamine, then any further ketamine dosing will be delayed until the following day (Day 2). In addition, subsequent subjects will receive a 33% reduction of the pre-surgery dose (i.e. 0.67 mg/kg). After Surgery: In the recovery room, when subjects are able to swallow, and if there were no adverse events from the pre-surgery ketamine dose, oral ketamine (1.0 mg/kg) will be administered (but no earlier than 8 hours after the pre-surgery dose). No doses will be administered after midnight. If adverse events have not resolved by the next morning (Day 2), then oral ketamine will be discontinued. In addition, subsequent subjects will receive a 33% reduction in the recovery room dose and/or the last dose of Day 1. Day 2 (first post-op day) Subjects will receive oral ketamine (1.0 mg/kg) 3 times/day. The first dose will be administered at 6 AM .If a subject experiences any adverse events after the first dose, but one that resolves within 8 hours after that dose, the second dose will be reduced by 33% (1.0 mg/mg to 0.67 mg/kg). If a subject experiences any adverse events after the second dose, but one that resolves within 8 hours, the dose will be reduced again by 33% (0.67 mg/kg to 0.45 mg/kg). If this dose reduction protocol does not eliminate adverse events, then oral ketamine will be discontinued. In addition, subsequent subjects will receive a 33% reduction in the Day 2 oral ketamine doses Day 3 (second post-op day) (Tapering Down Period) Subjects will receive oral ketamine at half of the previous day final dose (0.5 mg/kg if no dose reductions have occurred), 3 times a day. For example, if the subjects' dose is already at 0.45 mg/kg from the previous day reductions, then the third day dose will be 0.23 mg/kg. The first dose will be administered at 6 AM. Even on the third day if there are adverse events after any dose, but one that resolves within 8 hours after that dose, we will continue to reduce the dose by 33%. If this dose reduction protocol does not eliminate adverse events, then the subject will not receive any more ketamine. In addition, subsequent subjects will receive a 33% reduction in the Day 3 oral ketamine doses. While in the hospital for 3 days, should breakthrough pain occur, all subjects will receive standard of care pain control medication. All subjects will be discharged according to standard discharge protocol. Anticipated Adverse Events If a subject experiences adverse events, subjects will be closely monitored every hour until the event resolves. Adverse event duration and resolution time will be recorded. If the adverse event resolves, the next scheduled dose will be reduced by 33%. Each adverse event will be assessed by the Principal Investigator and a clinical relevance determination will be made.


Criteria:

Inclusion Criteria: 1. Adults of at least 18 years of age, but not older than 80 years 2. Due to undergo elective major amputation of the lower extremity (above the knee amputation (AKA), below the knee amputation (BKA), total knee amputation (TKA), transmetatarsal amputation (TMA), toe amputation) from all causes. Exclusion Criteria: 1. Pregnancy 2. Increased intracranial pressure or intraocular pressure 3. Allergy to ketamine 4. Morbid obesity (BMI > 40 kg/m2) 5. Significant comorbidity (ASA physical status classification > 3) 6. Inability to communicate with the investigators 7. Any history of known or suspected drug or alcohol abuse 8. History of impaired liver function 9. Significant history of hallucinations, delusions or other psychiatric medical condition the investigator feels will prevent assessment of adverse events of study drug. 10. Significant psychiatric history; a diagnosis of schizophrenia, bipolar disorder, or severe depression. 11. Exposure to cytochrome P450 3A4 inhibitors or inducers (including grapefruit products) within 2 weeks before enrollment; the inability to avoid these products during ketamine administration. 12. Poorly-controlled hypertension


NCT ID:

NCT02341963


Primary Contact:

Principal Investigator
Asokumar Buvanendran, M.D.
Professor Anesthesiology, Rush Unviersity Medical Center

Sherry J Robison, MBA
Phone: 312-942-2985
Email: Sherry_J_Robison@rush.edu


Backup Contact:

Email: mario_moric@rush.edu
Mario Moric
Phone: 312-942-2806


Location Contact:

Chicago, Illinois 60612
United States



There is no listed contact information for this specific location.

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 20, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.